Scott Boyle Biography and Net Worth

Chief Business Officer of C4 Therapeutics

Scott Boyle, Ph.D., MBA joined C4 Therapeutics in January 2022 as our Chief Business Officer. Previously, Scott was at Forma Therapeutics as Vice President, Business and Corporate Development. He has served clients in oncology and precision medicine at Boston Consulting Group (BCG) and built the business development function at Caris Life Sciences, where he held roles of increasing responsibility. Scott earned a Ph.D. in molecular biophysics and biochemistry from Yale University, an MBA from the Harvard Business School and a B.S. in biochemistry from Brigham Young University. He completed his postdoctoral fellowship at the Novartis Institute for Biomedical Research.

What is Scott N. Boyle's net worth?: The estimated net worth of Scott N. Boyle is at least $328.65 thousand as of February 14th, 2025. Dr. Boyle owns 110,842 shares of C4 Therapeutics stock worth more than $328,647 as of May 6th. This net worth approximation does not reflect any other investments that Dr. Boyle may own. Learn More about Scott N. Boyle's net worth.
How do I contact Scott N. Boyle?: The corporate mailing address for Dr. Boyle and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]. Learn More on Scott N. Boyle's contact information.
Has Scott N. Boyle been buying or selling shares of C4 Therapeutics?: Scott N. Boyle has not been actively trading shares of C4 Therapeutics in the last ninety days. Most recently, Scott N. Boyle sold 669 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.15, for a transaction totalling $2,107.35. Following the completion of the sale, the insider now directly owns 107,805 shares of the company's stock, valued at $339,585.75. Learn More on Scott N. Boyle's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Scott Boyle (Chief Business Officer), Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Leonard Reyno (https://immuneering.com/our-story/leadership/), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.
Are insiders buying or selling shares of C4 Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 10,000 shares worth more than $22,200.00. The most recent insider tranaction occured on January, 16th when insider Leonard Reyno sold 10,000 shares worth more than $22,200.00. Insiders at C4 Therapeutics own 8.7% of the company. Learn More about insider trades at C4 Therapeutics.
Information on this page was last updated on 1/16/2026.

Scott N. Boyle Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2025	Sell	669	$3.15	$2,107.35	107,805
2/14/2025	Sell	490	$3.15	$1,543.50	110,842

Scott N. Boyle Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $2.96

$2.90

$3.01

50 Day Range

MA: $2.80

$2.30

$3.59

2 Week Range

Now: $2.96

$1.21

$3.82

Volume

792,798 shs

Average Volume

2,363,431 shs

Market Capitalization

$325.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.77